Evotec, Roche Join For Alzheimer’s Drug | Chemical & Engineering News
Volume 89 Issue 37 | p. 12 | Concentrates
Issue Date: September 12, 2011

Evotec, Roche Join For Alzheimer’s Drug

Department: Business
News Channels: Biological SCENE
Keywords: Alzheimers’ disease, enzymes

Evotec and Roche are partnering to develop Evotec’s EVT 302, an inhibitor of monoamine oxidase type B (MAO-B), as a treatment for Alzheimer’s disease. MAO-B is an enzyme that breaks down the chemical messenger dopamine in the brain, increasing production of free radicals that contribute to the disease. Under the agreement, Roche will pay Evotec an up-front fee of $10 million. Evotec could receive milestone payments of $820 million as well as royalties. The compound, soon to enter clinical trials, was initially licensed from Roche to Evotec in 2006 for another indication.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment